Entrada Therapeutics, Inc.

NasdaqGM TRDA

Entrada Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 2.17

Entrada Therapeutics, Inc. Price to Sales Ratio (P/S) is 2.17 on January 14, 2025, a -38.94% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Entrada Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 4.14 on December 06, 2024, which is 90.57% above the current Price to Sales Ratio (P/S).
Entrada Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 1.78 on August 07, 2024, which is -18.04% below the current Price to Sales Ratio (P/S).
Entrada Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.74.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: TRDA

Entrada Therapeutics, Inc.

CEO	Mr. Dipal Doshi
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	6 Tide Street
Employees	177
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years